{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:22:15Z","timestamp":1763738535416,"version":"3.45.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03958-2","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:41:25Z","timestamp":1763736085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors and the role of chemotherapy in patients with pT3N0M0 gastric cancer: a propensity score matching analysis based on the SEER database"],"prefix":"10.1007","volume":"16","author":[{"given":"Tao","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangwang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"3958_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229.","journal-title":"CA Cancer J Clin."},{"key":"3958_CR2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00595-017-1493-y","volume":"47","author":"T Aoyama","year":"2017","unstructured":"Aoyama T, Yoshikawa T. Adjuvant therapy for locally advanced gastric cancer. Surg Today. 2017;47:1295\u2013302.","journal-title":"Surg Today"},{"key":"3958_CR3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.9738\/INTSURG-D-13-00176.1","volume":"99","author":"T Aoyama","year":"2014","unstructured":"Aoyama T, Yoshikawa T, Fujikawa H, Hayashi T, Ogata T, Cho H, et al. Exploratory analysis to find unfavorable subset of stage II gastric cancer for which surgery alone is the standard treatment; another target for adjuvant chemotherapy. Int Surg. 2014;99:835\u201341.","journal-title":"Int Surg"},{"key":"3958_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.5009\/gnl.2013.7.4.385","volume":"7","author":"SC Park","year":"2013","unstructured":"Park SC, Chun HJ. Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver. 2013;7:385\u201395.","journal-title":"Gut Liver"},{"key":"3958_CR5","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387\u201393.","journal-title":"J Clin Oncol"},{"key":"3958_CR6","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang H-K, Chung HC, Chung I-J, Kim S-W, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389\u201396.","journal-title":"Lancet Oncol"},{"key":"3958_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4","volume-title":"AJCC cancer staging manual","author":"FL Greene","year":"2002","unstructured":"Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.","edition":"6"},{"key":"3958_CR8","volume-title":"AJCC cancer staging manual","author":"SB Edge","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.","edition":"7"},{"key":"3958_CR9","volume-title":"AJCC cancer staging manual","author":"MB Amin","year":"2017","unstructured":"Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.","edition":"8"},{"key":"3958_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","volume":"20","author":"Japanese Gastric Cancer Association","year":"2017","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1\u201319.","journal-title":"Gastric Cancer"},{"key":"3958_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","volume":"24","author":"Japanese Gastric Cancer Association","year":"2021","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24:1\u201321.","journal-title":"Gastric Cancer"},{"key":"3958_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"F Wang","year":"2024","unstructured":"Wang F, Zhang X, Tang L, Wu Q, Cai M, Li Y, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 2024;44:127\u201372.","journal-title":"Cancer Commun"},{"key":"3958_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"key":"3958_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5230\/jgc.2019.19.e32","volume":"19","author":"Guideline Committee of the Korean Gastric Cancer Association (KGCA)","year":"2019","unstructured":"Guideline Committee of the Korean Gastric Cancer Association (KGCA). Development working group & review Panel. Korean practice guideline for gastric cancer 2018: an evidence-based, multi-disciplinary approach. J Gastric Cancer. 2019;19:1.","journal-title":"J Gastric Cancer"},{"key":"3958_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1634\/theoncologist.8-6-541","volume":"8","author":"LA Gloeckler Ries","year":"2003","unstructured":"Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the surveillance, epidemiology, and end results (SEER) program. Oncologist. 2003;8:541\u201352.","journal-title":"Oncologist"},{"key":"3958_CR16","volume-title":"International classification of diseases for oncology: ICD-O","year":"2000","unstructured":"Fritz AG, editor. International classification of diseases for oncology: ICD-O. 3rd ed. Geneva: World Health Organization; 2000.","edition":"3"},{"key":"3958_CR17","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.7150\/jca.19174","volume":"8","author":"M Honda","year":"2017","unstructured":"Honda M, Wong SL, Healy MA, Nakajima T, Watanabe M, Fukuma S, et al. Long-term trends in primary sites of gastric adenocarcinoma in Japan and the United States. J Cancer. 2017;8:1935\u201342.","journal-title":"J Cancer"},{"key":"3958_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00630","volume":"10","author":"S Li","year":"2020","unstructured":"Li S, Zang L. The effectiveness of gastrectomy with chemoradiotherapy among stage IV gastric adenocarcinoma: a population-based analysis. Front Oncol. 2020;10:630.","journal-title":"Front Oncol"},{"key":"3958_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","volume":"64","author":"P Laur\u00e9n","year":"1965","unstructured":"Laur\u00e9n P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal\u2010type carcinoma. Acta Pathol Microbiol Scand. 1965;64:31\u201349.","journal-title":"Acta Pathol Microbiol Scand"},{"key":"3958_CR20","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1158\/1055-9965.EPI-09-0250","volume":"18","author":"H Wu","year":"2009","unstructured":"Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the united States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev. 2009;18:1945\u201352.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"3958_CR21","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1002\/cncr.28913","volume":"120","author":"AM Stessin","year":"2014","unstructured":"Stessin AM, Sison C, Schwartz A, Ng J, Chao CKS, Li B. Does adjuvant radiotherapy benefit patients with diffuse-type gastric cancer? Results from the surveillance, epidemiology, and end results database. Cancer. 2014;120:3562\u20138.","journal-title":"Cancer"},{"key":"3958_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.gie.2019.03.002","volume":"90","author":"Z-Y Li","year":"2019","unstructured":"Li Z-Y, Zhang Q-W, Teng L-M, Zhang C-H, Huang Y. Comparable rates of lymph node metastasis and survival between diffuse type and intestinal type early gastric cancer patients: a large population-based study. Gastrointest Endosc. 2019;90:84-e9510.","journal-title":"Gastrointest Endosc"},{"key":"3958_CR23","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.7150\/jca.52123","volume":"12","author":"S Pan","year":"2021","unstructured":"Pan S, Yin S, Zhu Z, Liu F, Xu H. Decision-making of adjuvant therapy in pT1N1M0 gastric cancer: should radiotherapy be added to chemotherapy? A propensity score-matched analysis. J Cancer. 2021;12:1179\u201389.","journal-title":"J Cancer"},{"key":"3958_CR24","doi-asserted-by":"publisher","first-page":"6010","DOI":"10.1002\/cam4.2521","volume":"8","author":"T Shi","year":"2019","unstructured":"Shi T, Song X, Liu Q, Yang Y, Yu L, Liu B, et al. Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: a large population-based study. Cancer Med. 2019;8:6010\u201320.","journal-title":"Cancer Med"},{"key":"3958_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-019-1096-8","volume":"19","author":"Z-N Huang","year":"2019","unstructured":"Huang Z-N, Desiderio J, Chen Q-Y, Zheng C-H, Li P, Xie J-W, et al. Indications for adjuvant chemotherapy in patients with AJCC stage IIa T3N0M0 and T1N2M0 gastric cancer\u2014an East and West multicenter study. BMC Gastroenterol. 2019;19:205.","journal-title":"BMC Gastroenterol"},{"key":"3958_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cmpb.2010.02.004","volume":"100","author":"T Filleron","year":"2010","unstructured":"Filleron T, Laplanche A, Boher J-M, Kramar A. An R function to non-parametric and piecewise analysis of competing risks survival data. Comput Methods Programs Biomed. 2010;100:24\u201338.","journal-title":"Comput Methods Programs Biomed"},{"key":"3958_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"DE Ho","year":"2011","unstructured":"Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42:1\u201328.","journal-title":"J Stat Softw"},{"key":"3958_CR28","doi-asserted-by":"publisher","first-page":"108782","DOI":"10.1016\/j.ejso.2024.108782","volume":"51","author":"H Kondo","year":"2024","unstructured":"Kondo H, Sato S, Kunisaki C, Tanaka Y, Sato K, Kimura J, et al. Prognostic factors in patients with pathological T3N0M0 gastric cancer: a multi-institutional, retrospective study (YCOG2202). Eur J Surg Oncol. 2024;51:108782.","journal-title":"Eur J Surg Oncol"},{"key":"3958_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030553","volume":"13","author":"Y-F Chen","year":"2023","unstructured":"Chen Y-F, Chen M-Y, Le P-H, Chen T-H, Kuo C-J, Wang S-Y, et al. Prognostic factors and the role of adjuvant chemotherapy in pathological node-negative T3 gastric cancer. J Pers Med. 2023;13:553.","journal-title":"J Pers Med"},{"key":"3958_CR30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1245\/s10434-020-09063-8","volume":"28","author":"M Kang","year":"2020","unstructured":"Kang M, Youn HG, An JY, Choi M-G, Lee JH, Sohn TS, et al. Adjuvant chemotherapy vs. surgery alone for pT3N0M0 gastric cancer. Ann Surg Oncol. 2020;28:1437\u201344.","journal-title":"Ann Surg Oncol"},{"key":"3958_CR31","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1245\/s10434-015-4980-7","volume":"23","author":"K-G Lee","year":"2016","unstructured":"Lee K-G, Lee H-J, Oh S-Y, Yang J-Y, Ahn H-S, Suh Y-S, et al. Is there any role of adjuvant chemotherapy for T3N0M0 or T1N2M0 gastric cancer patients in stage II in the 7th TNM but stage I in the 6th TNM system? Ann Surg Oncol. 2016;23:1234\u201343.","journal-title":"Ann Surg Oncol"},{"key":"3958_CR32","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1002\/jso.26458","volume":"123","author":"A Rajabnejad","year":"2021","unstructured":"Rajabnejad A, Vaida F, Valasek M, Razzaque S, Fanta P, Horgan S, et al. Predictors and significance of histologic response to neoadjuvant therapy for gastric cancer. J Surg Oncol. 2021;123:1716\u201323.","journal-title":"J Surg Oncol"},{"key":"3958_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.49026","volume":"6","author":"SP Wu","year":"2023","unstructured":"Wu SP, Keshavjee SH, Yoon SS, Kwon S. Survival outcomes and patterns of care for stage II or III resected gastric cancer by race and ethnicity. JAMA Netw Open. 2023;6:e2349026.","journal-title":"JAMA Netw Open"},{"key":"3958_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000350873","volume":"30","author":"WO De Steur","year":"2013","unstructured":"De Steur WO, Dikken JL, Hartgrink HH. Lymph node dissection in resectable advanced gastric cancer. Dig Surg. 2013;30:96\u2013103.","journal-title":"Dig Surg"},{"key":"3958_CR35","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.3748\/wjg.v22.i10.2875","volume":"22","author":"M Degiuli","year":"2016","unstructured":"Degiuli M, De Manzoni G, Di Leo A, D\u2019Ugo D, Galasso E, Marrelli D, et al. Gastric cancer: current status of lymph node dissection. World J Gastroenterol. 2016;22:2875\u201393.","journal-title":"World J Gastroenterol"},{"key":"3958_CR36","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1245\/s10434-020-08387-9","volume":"27","author":"G-T Lin","year":"2020","unstructured":"Lin G-T, Chen Q-Y, Zhong Q, Zheng C-H, Li P, Xie J-W, et al. Intraoperative surrogate indicators of gastric cancer patients\u2019 long-term prognosis: the number of lymph nodes examined relates to the lymph node noncompliance rate. Ann Surg Oncol. 2020;27:3281\u201393.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"3958_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-023-03029-2","volume":"21","author":"D Du","year":"2023","unstructured":"Du D, Xie Y, Li X, Ni Z, Shi J, Huang H. De-escalating chemotherapy for stage I\u2013II gastric neuroendocrine carcinoma? A real-world competing risk analysis. World J Surg Oncol. 2023;21(1):142.","journal-title":"World J Surg Oncol"},{"key":"3958_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/1756284819867553","volume":"12","author":"J Fu","year":"2019","unstructured":"Fu J, Wu L, Ge C, Xu T, Li D, Fu W, et al. De-escalating chemotherapy for stage II colon cancer? Ther Adv Gastroenterol. 2019;12:1756284819867553.","journal-title":"Ther Adv Gastroenterol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03958-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03958-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03958-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:41:26Z","timestamp":1763736086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03958-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3958"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03958-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this is an observational study based on the SEER databse which is open to the public, approval of an ethics committee were unnecessary. This study used de-identified data from the SEER database which is open to the public, the informed consent was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the manuscript and agreed to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2139"}}